Anhui Anke BioTech Group

SHE:300009 China Biotechnology
Market Cap
$2.21 Billion
CN¥16.20 Billion CNY
Market Cap Rank
#6154 Global
#904 in China
Share Price
CN¥9.69
Change (1 day)
+0.31%
52-Week Range
CN¥7.59 - CN¥12.30
All Time High
CN¥127.71
Categories
Companies in China Biotechnology
About

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterf… Read more

Anhui Anke BioTech Group (300009) - Net Assets

Latest net assets as of September 2025: CN¥4.34 Billion CNY

Based on the latest financial reports, Anhui Anke BioTech Group (300009) has net assets worth CN¥4.34 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.10 Billion) and total liabilities (CN¥755.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥4.34 Billion
% of Total Assets 85.19%
Annual Growth Rate 21.88%
5-Year Change 46.83%
10-Year Change 240.06%
Growth Volatility 51.74

Anhui Anke BioTech Group - Net Assets Trend (2006–2024)

This chart illustrates how Anhui Anke BioTech Group's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Anhui Anke BioTech Group (2006–2024)

The table below shows the annual net assets of Anhui Anke BioTech Group from 2006 to 2024.

Year Net Assets Change
2024-12-31 CN¥4.30 Billion +9.35%
2023-12-31 CN¥3.93 Billion +15.60%
2022-12-31 CN¥3.40 Billion +17.16%
2021-12-31 CN¥2.90 Billion -0.85%
2020-12-31 CN¥2.93 Billion +8.47%
2019-12-31 CN¥2.70 Billion +34.26%
2018-12-31 CN¥2.01 Billion +14.24%
2017-12-31 CN¥1.76 Billion +23.43%
2016-12-31 CN¥1.43 Billion +12.79%
2015-12-31 CN¥1.26 Billion +63.48%
2014-12-31 CN¥773.47 Million +17.09%
2013-12-31 CN¥660.60 Million +13.89%
2012-12-31 CN¥580.03 Million +6.65%
2011-12-31 CN¥543.88 Million +4.13%
2010-12-31 CN¥522.30 Million +5.43%
2009-12-31 CN¥495.41 Million +233.29%
2008-12-31 CN¥148.64 Million +8.43%
2007-12-31 CN¥137.09 Million +12.37%
2006-12-31 CN¥122.00 Million --

Equity Component Analysis

This analysis shows how different components contribute to Anhui Anke BioTech Group's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 10608.7% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥1.62 Billion 39.28%
Common Stock CN¥1.67 Billion 40.55%
Other Components CN¥831.75 Million 20.17%
Total Equity CN¥4.12 Billion 100.00%

Anhui Anke BioTech Group Competitors by Market Cap

The table below lists competitors of Anhui Anke BioTech Group ranked by their market capitalization.

Company Market Cap
MMG Limited
PINK:MMLTF
 		$1.37 Billion
Bossard Holding AG
OTCGREY:BHAGF
 		$1.37 Billion
Teijin Limited
F:TIJ
 		$1.37 Billion
China TransInfo Technology Co Ltd
SHE:002373
 		$1.37 Billion
Ivanhoe Electric Inc.
NYSE MKT:IE
 		$1.37 Billion
Beijing Jingneng Power Co Ltd
SHG:600578
 		$1.37 Billion
Vermilion Energy Inc.
NYSE:VET
 		$1.36 Billion
Margun Enerji Uretim Sanayi ve Ticaret AS
IS:MAGEN
 		$1.36 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Anhui Anke BioTech Group's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 3,737,399,547 to 4,124,312,564, a change of 386,913,017 (10.4%).
  • Net income of 706,948,371 contributed positively to equity growth.
  • Dividend payments of 415,572,893 reduced retained earnings.
  • Share repurchases of 18,673,071 reduced equity.
  • Other comprehensive income decreased equity by 295,897,983.
  • Other factors increased equity by 410,108,593.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥706.95 Million +17.14%
Dividends Paid CN¥415.57 Million -10.08%
Share Repurchases CN¥18.67 Million -0.45%
Other Comprehensive Income CN¥-295.90 Million -7.17%
Other Changes CN¥410.11 Million +9.94%
Total Change CN¥- 10.35%

Book Value vs Market Value Analysis

This analysis compares Anhui Anke BioTech Group's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.95x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 85.45x to 3.95x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2006-12-31 CN¥0.11 CN¥9.69 x
2007-12-31 CN¥0.13 CN¥9.69 x
2008-12-31 CN¥0.15 CN¥9.69 x
2009-12-31 CN¥0.45 CN¥9.69 x
2010-12-31 CN¥0.48 CN¥9.69 x
2011-12-31 CN¥0.40 CN¥9.69 x
2012-12-31 CN¥0.42 CN¥9.69 x
2013-12-31 CN¥0.47 CN¥9.69 x
2014-12-31 CN¥0.53 CN¥9.69 x
2015-12-31 CN¥0.85 CN¥9.69 x
2016-12-31 CN¥0.89 CN¥9.69 x
2017-12-31 CN¥1.08 CN¥9.69 x
2018-12-31 CN¥1.22 CN¥9.69 x
2019-12-31 CN¥1.60 CN¥9.69 x
2020-12-31 CN¥1.73 CN¥9.69 x
2021-12-31 CN¥1.70 CN¥9.69 x
2022-12-31 CN¥1.96 CN¥9.69 x
2023-12-31 CN¥2.29 CN¥9.69 x
2024-12-31 CN¥2.45 CN¥9.69 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Anhui Anke BioTech Group utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 17.14%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 27.88%
  • • Asset Turnover: 0.49x
  • • Equity Multiplier: 1.25x
  • Recent ROE (17.14%) is above the historical average (14.21%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2006 14.23% 12.31% 0.57x 2.04x CN¥4.67 Million
2007 18.04% 18.04% 0.53x 1.88x CN¥10.13 Million
2008 23.25% 22.08% 0.70x 1.50x CN¥19.69 Million
2009 9.00% 23.38% 0.35x 1.09x CN¥-4.97 Million
2010 10.00% 22.81% 0.39x 1.13x CN¥24.37K
2011 11.64% 23.64% 0.44x 1.11x CN¥8.93 Million
2012 12.75% 21.88% 0.52x 1.13x CN¥15.94 Million
2013 13.60% 20.88% 0.57x 1.14x CN¥23.81 Million
2014 14.87% 20.25% 0.59x 1.24x CN¥35.96 Million
2015 11.20% 21.43% 0.45x 1.15x CN¥14.56 Million
2016 14.52% 23.23% 0.43x 1.45x CN¥61.40 Million
2017 16.55% 25.34% 0.49x 1.34x CN¥109.96 Million
2018 13.70% 18.01% 0.58x 1.32x CN¥71.14 Million
2019 4.74% 7.27% 0.53x 1.23x CN¥-138.20 Million
2020 12.66% 21.10% 0.49x 1.24x CN¥75.38 Million
2021 7.42% 9.53% 0.59x 1.32x CN¥-72.03 Million
2022 21.92% 30.17% 0.55x 1.33x CN¥382.40 Million
2023 22.67% 29.56% 0.58x 1.32x CN¥473.49 Million
2024 17.14% 27.88% 0.49x 1.25x CN¥294.52 Million

Industry Comparison

This section compares Anhui Anke BioTech Group's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,043,310,248
  • Average return on equity (ROE) among peers: 14.20%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Anhui Anke BioTech Group (300009) CN¥4.34 Billion 14.23% 0.17x $1.37 Billion
Shenzhen CAU Technology Co Ltd (000004) $124.02 Million 4.50% 1.13x $80.66 Million
Pacific Shuanglin Bio pharmacy Co Ltd (000403) $525.49 Million 14.76% 1.41x $1.02 Billion
Nanhua Bio Medicine Co Ltd (000504) $174.34 Million 36.11% 1.61x $288.51 Million
Jiangsu Sihuan Bioengineering Co Ltd (000518) $642.80 Million -4.58% 0.44x $244.62 Million
Chengzhi Shareholding Co Ltd (000990) $1.69 Billion 3.06% 0.97x $850.04 Million
Hualan Biological EngineeringInc (002007) $1.86 Billion 32.78% 0.08x $2.00 Billion
Da An Gene Co Ltd of Sun Yat-Sen University (002030) $2.09 Billion 4.42% 0.71x $784.18 Million
Shanghai RAAS Blood Products Co Ltd Class A (002252) $831.21 Million 22.32% 0.12x $3.76 Billion
Baolingbao Biology Co Ltd (002286) $2.04 Billion 5.44% 0.31x $398.99 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287) $456.61 Million 23.20% 0.29x $347.95 Million